These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 29751154)

  • 1. Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome.
    Kuang FL; Fay MP; Ware J; Wetzler L; Holland-Thomas N; Brown T; Ortega H; Steinfeld J; Khoury P; Klion AD
    J Allergy Clin Immunol Pract; 2018; 6(5):1518-1527.e5. PubMed ID: 29751154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5.
    Rothenberg ME; Roufosse F; Faguer S; Gleich GJ; Steinfeld J; Yancey SW; Mavropoulou E; Kwon N;
    J Allergy Clin Immunol Pract; 2022 Sep; 10(9):2367-2374.e3. PubMed ID: 35568330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.
    Roufosse F; de Lavareille A; Schandené L; Cogan E; Georgelas A; Wagner L; Xi L; Raffeld M; Goldman M; Gleich GJ; Klion A
    J Allergy Clin Immunol; 2010 Oct; 126(4):828-835.e3. PubMed ID: 20810155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes.
    Roufosse FE; Kahn JE; Gleich GJ; Schwartz LB; Singh AD; Rosenwasser LJ; Denburg JA; Ring J; Rothenberg ME; Sheikh J; Haig AE; Mallett SA; Templeton DN; Ortega HG; Klion AD
    J Allergy Clin Immunol; 2013 Feb; 131(2):461-7.e1-5. PubMed ID: 23040887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypereosinophilic Syndrome Subtype Predicts Responsiveness to Glucocorticoids.
    Khoury P; Abiodun AO; Holland-Thomas N; Fay MP; Klion AD
    J Allergy Clin Immunol Pract; 2018; 6(1):190-195. PubMed ID: 28757367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome.
    Reiter A; Lefevre G; Cid MC; Kwon N; Mavropolou E; Yancey SW; Steinfeld J
    Front Immunol; 2022; 13():840974. PubMed ID: 35493455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.
    Garrett JK; Jameson SC; Thomson B; Collins MH; Wagoner LE; Freese DK; Beck LA; Boyce JA; Filipovich AH; Villanueva JM; Sutton SA; Assa'ad AH; Rothenberg ME
    J Allergy Clin Immunol; 2004 Jan; 113(1):115-9. PubMed ID: 14699394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
    Schwartz LB; Sheikh J; Singh A
    Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial.
    Roufosse F; Kahn JE; Rothenberg ME; Wardlaw AJ; Klion AD; Kirby SY; Gilson MJ; Bentley JH; Bradford ES; Yancey SW; Steinfeld J; Gleich GJ;
    J Allergy Clin Immunol; 2020 Dec; 146(6):1397-1405. PubMed ID: 32956756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.
    Ogbogu PU; Bochner BS; Butterfield JH; Gleich GJ; Huss-Marp J; Kahn JE; Leiferman KM; Nutman TB; Pfab F; Ring J; Rothenberg ME; Roufosse F; Sajous MH; Sheikh J; Simon D; Simon HU; Stein ML; Wardlaw A; Weller PF; Klion AD
    J Allergy Clin Immunol; 2009 Dec; 124(6):1319-25.e3. PubMed ID: 19910029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
    Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mepolizumab-a novel option for the treatment of hypereosinophilic syndrome in childhood.
    Schwarz C; Müller T; Lau S; Parasher K; Staab D; Wahn U
    Pediatr Allergy Immunol; 2018 Feb; 29(1):28-33. PubMed ID: 28986919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of patients with the hypereosinophilic syndrome with mepolizumab.
    Rothenberg ME; Klion AD; Roufosse FE; Kahn JE; Weller PF; Simon HU; Schwartz LB; Rosenwasser LJ; Ring J; Griffin EF; Haig AE; Frewer PI; Parkin JM; Gleich GJ;
    N Engl J Med; 2008 Mar; 358(12):1215-28. PubMed ID: 18344568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of glucocorticoid resistance in hypereosinophilic syndromes.
    Stokes K; Yoon P; Makiya M; Gebreegziabher M; Holland-Thomas N; Ware J; Wetzler L; Khoury P; Klion AD
    Clin Exp Allergy; 2019 Dec; 49(12):1598-1604. PubMed ID: 31657082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
    Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of disease flares and impact of mepolizumab in patients with hypereosinophilic syndrome.
    Pane F; Lefevre G; Kwon N; Bentley JH; Yancey SW; Steinfeld J
    Front Immunol; 2022; 13():935996. PubMed ID: 36091012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study.
    Gleich GJ; Roufosse F; Chupp G; Faguer S; Walz B; Reiter A; Yancey SW; Bentley JH; Steinfeld J;
    J Allergy Clin Immunol Pract; 2021 Dec; 9(12):4431-4440.e1. PubMed ID: 34389506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes.
    Chen MM; Roufosse F; Wang SA; Verstovsek S; Durrani SR; Rothenberg ME; Pongdee T; Butterfield J; Lax T; Wechsler ME; Stein ML; Ogbogu PU; Kahwash BM; Mathur SK; Simon D; Akuthota P; Holland N; Wetzler L; Ware JM; Guo C; Fay MP; Khoury P; Klion AD; Bochner BS
    J Allergy Clin Immunol Pract; 2022 May; 10(5):1217-1228.e3. PubMed ID: 35181548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome.
    Klion AD; Law MA; Noel P; Kim YJ; Haverty TP; Nutman TB
    Blood; 2004 Apr; 103(8):2939-41. PubMed ID: 15070668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mepolizumab and eosinophil-mediated disease.
    Walsh GM
    Curr Med Chem; 2009; 16(36):4774-8. PubMed ID: 19929788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.